



**April 24, 2006**

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Revisions to Communicable Disease Control Manual, Chapter 2 – Immunization Program**

Please note the following changes to the Communicable Disease Control Manual, Chapter 2 – Immunization Program:

**Section II – Immunization Schedules**

Pages 2, 6, 8 and 14:

- Correction of errors: Tdap changed to Tdap in appropriate sections; DTaP/IPV/Hib changed to DaPT/IPV/Hib on page 8.

**Section VII – Biological Products**

Page 3, Diphtheria, Acellular Pertussis, Tetanus, Polio (Quadracel™):

- Footnote specifying minimum intervals between doses in the series

Page 29, Immune Globulin Preparations or Blood: Timing Intervals For Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:

- New product listed: Varicella Zoster Immune Globulin (Human) VariZIG™

Please note that the biological product page for VariZIG™ will be available at a later date.

Page 30, Immune Globulin Preparations or Blood: Timing Intervals For Vaccines Containing Live Measles, Mumps, Rubella, or Varicella Virus:

- New footnote<sup>♣</sup> stating that the timing consideration for anti-Rho (D) immune globulin pertains only to rubella-containing vaccines.

**Administrative Circular # 2006:06**



Page 34, Measles, Mumps, Rubella vaccine (MMR):

- Health and child care students born after 1957 are eligible for a free second dose of MMR vaccine

Pages 35, 37 and 38a, Meningococcal C conjugate vaccines:

- Men who have sex with men are included in the list of persons eligible for vaccine.

Page 41, Pneumococcal conjugate vaccine (Prevnar™); Pages 43 and 43<sup>a</sup>, Polysaccharide Pneumococcal vaccines:

- For clarity, cystic fibrosis is added to the eligibility list for these vaccines. This condition was previously included under “chronic cardiorespiratory disease.”
- “Chronic cardiorespiratory disease” is reworded to “chronic heart or lung disease.” Asthma is excluded as an indication for vaccine, unless management involves ongoing high dose oral corticosteroid therapy.

Pages 42, 43, 43a re: pneumococcal vaccines:

- New footnote: “If high risk children  $\geq 2$  years of age received pneumococcal polysaccharide vaccine first, offer pneumococcal conjugate vaccine at least 8 weeks after the polysaccharide vaccine.”

Page 53, Tetanus-Diphtheria-acellular Pertussis (Tdap) (Adacel™):

- New footnote • “According to the National Advisory Committee on Immunization (NACI), Tdap can be administered to all those  $\geq 7$  years of age (there is no upper age limit for its administration). This differs from the information in the Tdap product monograph.”

Pages 63 and 65, Varicella vaccine indications:

- New eligibility groups as of April 1/06:
  - active catch-up program for susceptible children 18 to 47 months of age
  - susceptible children, adolescents, and adults at opportune health encounters

Pages 64 and 66, Varicella vaccine contraindications:

- New footnote ♦ stating that the timing consideration for anti-Rho (D) immune globulin pertains only to rubella-containing vaccines.

Page 67, Yellow Fever Vaccine:

- Under vaccine precautions, the age has been changed to  $\geq 60$  years of age, to reflect a recent PHAC advisory.

**Please remove and destroy the following pages from Communicable Disease Control Manual, Chapter 2 – Immunization Program:**

**Section II – Immunization Schedules**

Pages 2 and 8  
Page 6  
Page 14

Dated October 2005  
Dated February 2006  
Dated September 2004

**Section VII – Biological Products**

Page 3  
Page 29  
Page 30  
Pages 34  
Pages 35, 37, 38a and 53  
Pages 41, 43, 43a  
Page 42  
Pages 63, 64, 65, 66  
Page 67

Dated November 2002  
Dated August 2004  
Dated June 2003  
Dated November 2005  
Dated January 2006  
Dated October 2005  
Dated March 2005  
Dated June 2005  
Dated December 2005

**Insert the following pages in the Communicable Disease Control Manual, Chapter 2 - Immunization Program:**

**Section II – Immunization Schedules**

Pages 2, 6, 8 and 14

Dated April 2006

**Section VII – Biological Products**

Pages 3, 29, 30, 34, 35, 37, 38a, 41, 42, 43, 43a, 53  
and 63 to 67

Dated April 2006



If you have any questions or concerns, please contact Karen Pielak, Nurse Epidemiologist, or Cheryl McIntyre, Associate Nurse Epidemiologist, at telephone (604)660-6061, fax (604)660-0197 or by email at [karen.pielak@bccdc.ca](mailto:karen.pielak@bccdc.ca) or [cheryl.mcintyre@bccdc.ca](mailto:cheryl.mcintyre@bccdc.ca)

Sincerely,

David Patrick  
 Director  
 Epidemiology Services  
 BC Centre for Disease Control

DMP/kka

pc: Dr Perry Kendall  
 Provincial Health Officer  
 Ministry of Health Services

Dr. Eric Young  
 Deputy Provincial Health Officer  
 Ministry of Health Services

Dr. Bob Fisk  
 Medical Consultant  
 Non-Communicable Disease  
 Ministry of Health Planning

Warren O'Briain  
 Executive Director  
 Comm Disease and Addiction Prevention  
 Ministry of Health Services

Linda Poirier  
 Acting Manager, Communicable Disease Prevention --Immunization  
 Communicable Disease and Addiction Prevention  
 Ministry of Health Services